Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial

Although some intravenous drugs have been used to treat coronavirus disease 2019 (COVID-19), no effective antiviral agents are currently available in the outpatient setting. We aimed to evaluate the efficacy and adverse events of 14-day ciclesonide treatment vs. standard care for patients with mild-...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Joon-Young, Yoon, Jin-Gu, Seo, Yu-Bin, Lee, Jacob, Eom, Joong-Sik, Lee, Jin-Soo, Choi, Won-Suk, Lee, Eun-Young, Choi, Young-Ah, Hyun, Hak-Jun, Seong, Hye, Noh, Ji-Yun, Cheong, Hee-Jin, Kim, Woo-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396813/
https://www.ncbi.nlm.nih.gov/pubmed/34441840
http://dx.doi.org/10.3390/jcm10163545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396813/
https://www.ncbi.nlm.nih.gov/pubmed/34441840
http://dx.doi.org/10.3390/jcm10163545

Ejemplares similares